Plivensia (sirukumab)
- Region
- 🇪🇺 EU
- Active substance
- sirukumab
- Company
- Janssen-Cilag International NV
- Status
- Application withdrawn
- Therapeutic area
- Arthritis, Rheumatoid
- Application
- EMEA/H/C/004165
- ATC
- L04AC
- Official record
- www.ema.europa.eu
Indication
Treatment of rheumatoid arthritis.
Regulatory milestones
No milestones recorded in the last year.
Follow Plivensia
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.